CIK 0000728387 · Non-accelerated filer<br>Smaller reporting company
Perspective Therapeutics, Inc.
Sign in to watch- Ticker
- CATX
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 411458152
- Phone
- 206-676-0900
- Business address
- 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE, WA, 98121
- Former names
- IsoRay, Inc., Isoray, Inc., CENTURY PARK PICTURES CORP
- Open-market buys, last 90 days
- $72,488
- in 2 filings
- Open-market sales, last 90 days
- $1,622,534
- in 5 filings
Net −$1,550,047. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-23 | Austin Mark John Controller/Prin Fin&Acct Offic | Grant or award · Stock Options (right to buy) | +30,000 | 255,000 | ||
| 2020-06-23 | Streeter Jennifer COO & VP of HR | Grant or award · Stock Options (right to buy) | +150,000 | 500,000 | ||
| 2020-06-23 | Cavanagh William Chief R&D Officer | Grant or award · Stock Options (right to buy) | +150,000 | 701,660 | ||
| 2020-06-23 | Cline Krista Dir. of Operations, Secretary | Grant or award · Stock Options (right to buy) | +30,000 | 227,500 | ||
| 2020-06-23 | Hunt Jonathan Robert Chief Financial Officer | Grant or award · Stock Options (right to buy) | +150,000 | 450,000 | ||
| 2020-06-23 | Woods Lori A CEO | Grant or award · Stock Options (right to buy) | +250,000 | 587,500 | ||
| 2020-02-03 | Woods Lori A CEO | Option exercise | +75,000 | $0.61 | $45K | 355,000 |
| 2020-02-03 | Woods Lori A CEO | Option exercise | +125,000 | $0.46 | $58K | 480,000 |
| 2020-02-03 | Woods Lori A CEO | Option exercise | +62,500 | $0.43 | $27K | 542,500 |
| 2020-02-03 | Woods Lori A CEO | Option exercise · Stock Options (right to buy) | −75,000 | 25,000 | ||
| 2020-02-03 | Woods Lori A CEO | Option exercise · Stock Options (right to buy) | −125,000 | 125,000 | ||
| 2020-02-03 | Woods Lori A CEO | Option exercise · Stock Options (right to buy) | −62,500 | 187,500 | ||
| 2019-11-20 | Krachon Michael VP of Sales & Marketing | Purchase | +50,000 | $0.39 | $19K | 50,000 |
| 2019-11-15 | Woods Lori A CEO | Purchase | +25,000 | $0.39 | $10K | 280,000 |
| 2019-11-15 | Cavanagh William Chief R&D Officer | Purchase | +10,000 | $0.39 | $4K | 20,000 |
| 2019-11-14 | Woods Lori A CEO | Purchase | +125,000 | $0.40 | $50K | 255,000 |
| 2019-06-18 | Hunt Jonathan Robert Chief Financial Officer | Grant or award · Stock Options (right to buy) | +150,000 | 300,000 | ||
| 2019-06-18 | Cavanagh William Chief R&D Officer | Grant or award · Stock Options (right to buy) | +150,000 | 551,660 | ||
| 2019-06-18 | Krachon Michael VP of Sales & Marketing | Grant or award · Stock Options (right to buy) | +150,000 | 525,000 | ||
| 2019-06-18 | Streeter Jennifer VP of Human Resources | Grant or award · Stock Options (right to buy) | +150,000 | 350,000 |
Page 10 of 26 · 504 trades